5 YEARS IN THE MAKING, TARGETED NATIONAL LUNG CANCER SCREENING PROGRAM COMMENCES IN 2025 Lung Foundation Australia CEO talks about opportunity to treat patients presenting at early stage instead of late stage
Australian Health Journal SEGMENT
Filmed in Adelaide | February 2025
INTERVIEWED
Mark Brooke, Chief Executive Officer
Lung Foundation Australia
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
The conference theme, Evolution and Revolution in Lung Cancer, was chosen in recognition of the historic significance of 2025. Mr Brooke emphasised the importance of the National Lung Cancer Screening Program, which is set to begin on July 1st.
The Australian Government’s $267 million investment in the National Lung Cancer Screening Program aims to vastly improve lung cancer detection, treatment, and survivorship. When launched it will be Australia’s first new screening program in over 20 years.
Following a request from the Australian Government, Cancer Australia undertook an enquiry into lung cancer screening, publishing a report that informed the development of the NLCSP.
As the health peak advisory body to the Department of Health and Aged Care, the Lung Foundation aims to amplify the lived experiences of patients within this program. After nearly five years of preparation, the initiative is a crucial step in moving lung cancer diagnoses from late stages (three and four) to early stages (one and two), significantly improving patient care.
Mr Brooke expressed optimism that the timing for this screening program is ideal for Australia, given that lung cancer is the nation’s leading cancer killer. The program’s implementation is particularly challenging because it integrates with General Practice, requiring collaboration from healthcare professionals. While acknowledging potential hurdles, Mr Brooke is confident that the organisation and preparation for the program are well on track.
The program specifically addresses the needs of priority populations, including Aboriginal and Torres Strait Islander communities, who are disproportionately affected by lung cancer. Efforts have been made to provide culturally safe experiences and mobile CT services through partnerships with organisations like Heart of Australia, ensuring access for rural and remote populations.
Over the past five years, the Lung Foundation has collaborated with state governments to support the role of specialist lung cancer nurses. This initiative has proven to enhance timely care and improve patient pathways, ultimately striving for better outcomes in lung cancer treatment.
-
New bar for cosmetic plastic surgeon accreditation
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Contrasting Population Needs and Alternative Funding Models
Dr Jaspreet Saini is a GP with a decade of experience, practicing in West Pennant Hills and Rooty Hill, New South Wales. He began his medical journey at Monash University, followed by internships and residency at Blacktown Hospital, in Western Sydney. Instead of confining himself to a single specialty, he pursued general practice to explore various facets of medicine.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
